Innoviva Inc
NASDAQ:INVA

Watchlist Manager
Innoviva Inc Logo
Innoviva Inc
NASDAQ:INVA
Watchlist
Price: 19.68 USD -1.6%
Market Cap: 1.2B USD
Have any thoughts about
Innoviva Inc?
Write Note

Intrinsic Value

The intrinsic value of one INVA stock under the Base Case scenario is 18.77 USD. Compared to the current market price of 19.68 USD, Innoviva Inc is Overvalued by 5%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

INVA Intrinsic Value
18.77 USD
Overvaluation 5%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Innoviva Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for INVA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about INVA?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Innoviva Inc

Provide an overview of the primary business activities
of Innoviva Inc.

What unique competitive advantages
does Innoviva Inc hold over its rivals?

What risks and challenges
does Innoviva Inc face in the near future?

Summarize the latest earnings call
of Innoviva Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Innoviva Inc.

Provide P/S
for Innoviva Inc.

Provide P/E
for Innoviva Inc.

Provide P/OCF
for Innoviva Inc.

Provide P/FCFE
for Innoviva Inc.

Provide P/B
for Innoviva Inc.

Provide EV/S
for Innoviva Inc.

Provide EV/GP
for Innoviva Inc.

Provide EV/EBITDA
for Innoviva Inc.

Provide EV/EBIT
for Innoviva Inc.

Provide EV/OCF
for Innoviva Inc.

Provide EV/FCFF
for Innoviva Inc.

Provide EV/IC
for Innoviva Inc.

Show me price targets
for Innoviva Inc made by professional analysts.

What are the Revenue projections
for Innoviva Inc?

How accurate were the past Revenue estimates
for Innoviva Inc?

What are the Net Income projections
for Innoviva Inc?

How accurate were the past Net Income estimates
for Innoviva Inc?

What are the EPS projections
for Innoviva Inc?

How accurate were the past EPS estimates
for Innoviva Inc?

What are the EBIT projections
for Innoviva Inc?

How accurate were the past EBIT estimates
for Innoviva Inc?

Compare the revenue forecasts
for Innoviva Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Innoviva Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Innoviva Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Innoviva Inc compared to its peers.

Compare the P/E ratios
of Innoviva Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Innoviva Inc with its peers.

Analyze the financial leverage
of Innoviva Inc compared to its main competitors.

Show all profitability ratios
for Innoviva Inc.

Provide ROE
for Innoviva Inc.

Provide ROA
for Innoviva Inc.

Provide ROIC
for Innoviva Inc.

Provide ROCE
for Innoviva Inc.

Provide Gross Margin
for Innoviva Inc.

Provide Operating Margin
for Innoviva Inc.

Provide Net Margin
for Innoviva Inc.

Provide FCF Margin
for Innoviva Inc.

Show all solvency ratios
for Innoviva Inc.

Provide D/E Ratio
for Innoviva Inc.

Provide D/A Ratio
for Innoviva Inc.

Provide Interest Coverage Ratio
for Innoviva Inc.

Provide Altman Z-Score Ratio
for Innoviva Inc.

Provide Quick Ratio
for Innoviva Inc.

Provide Current Ratio
for Innoviva Inc.

Provide Cash Ratio
for Innoviva Inc.

What is the historical Revenue growth
over the last 5 years for Innoviva Inc?

What is the historical Net Income growth
over the last 5 years for Innoviva Inc?

What is the current Free Cash Flow
of Innoviva Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Innoviva Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Innoviva Inc

Current Assets 400.6m
Cash & Short-Term Investments 260.6m
Receivables 91.1m
Other Current Assets 48.9m
Non-Current Assets 831m
Long-Term Investments 507.7m
PP&E 3.3m
Intangibles 302.3m
Other Non-Current Assets 17.7m
Current Liabilities 223.8m
Accounts Payable 4.2m
Accrued Liabilities 20.8m
Other Current Liabilities 198.8m
Non-Current Liabilities 339.3m
Long-Term Debt 256m
Other Non-Current Liabilities 83.3m
Efficiency

Earnings Waterfall
Innoviva Inc

Revenue
352.7m USD
Cost of Revenue
-42.6m USD
Gross Profit
310.2m USD
Operating Expenses
-148.9m USD
Operating Income
161.3m USD
Other Expenses
-96.7m USD
Net Income
64.6m USD

Free Cash Flow Analysis
Innoviva Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

INVA Profitability Score
Profitability Due Diligence

Innoviva Inc's profitability score is 68/100. The higher the profitability score, the more profitable the company is.

Positive Free Cash Flow
Exceptional 3-Year Average ROE
Positive Gross Profit
Positive Operating Income
68/100
Profitability
Score

Innoviva Inc's profitability score is 68/100. The higher the profitability score, the more profitable the company is.

INVA Solvency Score
Solvency Due Diligence

Innoviva Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
Low D/E
Long-Term Solvency
Short-Term Solvency
64/100
Solvency
Score

Innoviva Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

INVA Price Targets Summary
Innoviva Inc

Wall Street analysts forecast INVA stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for INVA is 18.36 USD with a low forecast of 18.18 USD and a high forecast of 18.9 USD.

Lowest
Price Target
18.18 USD
8% Downside
Average
Price Target
18.36 USD
7% Downside
Highest
Price Target
18.9 USD
4% Downside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for INVA?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for INVA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

INVA News

Other Videos

Profile

Innoviva Inc Logo
Innoviva Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

1.2B USD

Dividend Yield

0%

Description

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. The company is headquartered in Burlingame, California and currently employs 5 full-time employees. The company went IPO on 2004-10-05. The firm's royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/ vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/ vilanterol, UMEC/VI) and TRELEGY ELLIPTA (the combination FF/UMEC/VI). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement, the Company is entitled to receive royalties from GSK on sales of RELVAR/BREO ELLIPTA and royalties from the sales of ANORO ELLIPTA. RELVAR/BREO ELLIPTA is a once-daily combination medicine consisting of a LABA, vilanterol (VI), and an inhaled corticosteroid (ICS), fluticasone furoate (FF). ANORO ELLIPTA is a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with an LABA, VI. TRELEGY ELLIPTA (the combination FF/UMEC/VI), a once-daily combination medicine consisting of an ICS, LAMA, and LABA.

Contact

CALIFORNIA
Burlingame
1350 Old Bayshore Highway, Suite 400
+16502389600.0
www.inva.com

IPO

2004-10-05

Employees

5

Officers

Chief Executive Officer
Mr. Pavel Raifeld C.F.A.
Chief Financial Officer
Mr. Stephen Basso M.B.A.
Chief Accounting Officer & Secretary
Ms. Marianne Zhen CPA
Chief Commercial Officer-Innoviva Specialty Therapeutics, Inc.
Ms. Patricia M. Drake

See Also

Discover More
What is the Intrinsic Value of one INVA stock?

The intrinsic value of one INVA stock under the Base Case scenario is 18.77 USD.

Is INVA stock undervalued or overvalued?

Compared to the current market price of 19.68 USD, Innoviva Inc is Overvalued by 5%.

Back to Top